> top > docs > PubMed:26094080 > annotations

PubMed:26094080 JSONTXT

Annnotations TAB JSON ListView MergeView

sentences

Id Subject Object Predicate Lexical cue
TextSentencer_T1 0-6 Sentence denotes CHAMP:
TextSentencer_T2 7-239 Sentence denotes A Phase II Study of Panitumumab With Pemetrexed and Cisplatin Versus Pemetrexed and Cisplatin in the Treatment of Patients With Advanced-Stage Primary Nonsquamous Non-Small-Cell Lung Cancer With Particular Regard to the KRAS Status.
TextSentencer_T3 240-253 Sentence denotes INTRODUCTION:
TextSentencer_T4 254-608 Sentence denotes The aim of the study was to investigate the efficacy and tolerability of panitumumab, a fully human antiepidermal growth factor receptor monoclonal antibody, in combination with pemetrexed/cisplatin in patients with stage IIIB to IV primary nonsquamous non-small-cell lung cancer and wild type V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS).
TextSentencer_T5 609-731 Sentence denotes Results were compared with those obtained in a control group of patients who received a pemetrexed/cisplatin regimen only.
TextSentencer_T6 732-753 Sentence denotes PATIENTS AND METHODS:
TextSentencer_T7 754-826 Sentence denotes This was a phase II, randomized, open-label study with 2 treatment arms.
TextSentencer_T8 827-1007 Sentence denotes In total, 96 patients received panitumumab at a dose of 9 mg/kg in combination with pemetrexed 500 mg/m(2) and cisplatin 75 mg/m(2) (n = 49) or pemetrexed/cisplatin alone (n = 47).
TextSentencer_T9 1008-1078 Sentence denotes The primary outcome measure was progression-free survival at 6 months.
TextSentencer_T10 1079-1193 Sentence denotes Secondary end points of the study included overall survival, tumor response, quality of life, and safety outcomes.
TextSentencer_T11 1194-1268 Sentence denotes The CHAMP study is registered with ClinicalTrials.gov, number NCT01088620.
TextSentencer_T12 1269-1277 Sentence denotes RESULTS:
TextSentencer_T13 1278-1539 Sentence denotes Progression-free survival at 6 months did not indicate a benefit of panitumumab as a supplement to the standard therapy of pemetrexed/cisplatin whereas the overall survival showed a clear difference between the treatment groups in favor of the standard therapy.
TextSentencer_T14 1540-1662 Sentence denotes Results might be affected by the higher rates of serious adverse events and higher death rates within the panitumumab arm.
TextSentencer_T15 1663-1675 Sentence denotes CONCLUSIONS:
TextSentencer_T16 1676-2069 Sentence denotes Results from the present study indicate that combination of cisplatin/pemetrexed with panitumumab should not be recommended for patients with adenocarcinoma and KRAS wild type because of lack of efficacy, lack of improvement of quality of life, and because of the increase in toxicity rates compared with patients in the control arm, who received standard chemotherapy of pemetrexed/cisplatin.
T1 0-6 Sentence denotes CHAMP:
T2 7-239 Sentence denotes A Phase II Study of Panitumumab With Pemetrexed and Cisplatin Versus Pemetrexed and Cisplatin in the Treatment of Patients With Advanced-Stage Primary Nonsquamous Non-Small-Cell Lung Cancer With Particular Regard to the KRAS Status.
T3 240-253 Sentence denotes INTRODUCTION:
T4 254-608 Sentence denotes The aim of the study was to investigate the efficacy and tolerability of panitumumab, a fully human antiepidermal growth factor receptor monoclonal antibody, in combination with pemetrexed/cisplatin in patients with stage IIIB to IV primary nonsquamous non-small-cell lung cancer and wild type V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS).
T5 609-731 Sentence denotes Results were compared with those obtained in a control group of patients who received a pemetrexed/cisplatin regimen only.
T6 732-753 Sentence denotes PATIENTS AND METHODS:
T7 754-826 Sentence denotes This was a phase II, randomized, open-label study with 2 treatment arms.
T8 827-1007 Sentence denotes In total, 96 patients received panitumumab at a dose of 9 mg/kg in combination with pemetrexed 500 mg/m(2) and cisplatin 75 mg/m(2) (n = 49) or pemetrexed/cisplatin alone (n = 47).
T9 1008-1078 Sentence denotes The primary outcome measure was progression-free survival at 6 months.
T10 1079-1193 Sentence denotes Secondary end points of the study included overall survival, tumor response, quality of life, and safety outcomes.
T11 1194-1268 Sentence denotes The CHAMP study is registered with ClinicalTrials.gov, number NCT01088620.
T12 1269-1277 Sentence denotes RESULTS:
T13 1278-1539 Sentence denotes Progression-free survival at 6 months did not indicate a benefit of panitumumab as a supplement to the standard therapy of pemetrexed/cisplatin whereas the overall survival showed a clear difference between the treatment groups in favor of the standard therapy.
T14 1540-1662 Sentence denotes Results might be affected by the higher rates of serious adverse events and higher death rates within the panitumumab arm.
T15 1663-1675 Sentence denotes CONCLUSIONS:
T16 1676-2069 Sentence denotes Results from the present study indicate that combination of cisplatin/pemetrexed with panitumumab should not be recommended for patients with adenocarcinoma and KRAS wild type because of lack of efficacy, lack of improvement of quality of life, and because of the increase in toxicity rates compared with patients in the control arm, who received standard chemotherapy of pemetrexed/cisplatin.

DisGeNET5_gene_disease

Id Subject Object Predicate Lexical cue
26094080-0#0#5#gene283489 0-5 gene283489 denotes CHAMP
26094080-0#0#5#gene54456 0-5 gene54456 denotes CHAMP
26094080-0#227#231#gene3845 227-231 gene3845 denotes KRAS
26094080-0#170#196#diseaseC0007131 170-196 diseaseC0007131 denotes Non-Small-Cell Lung Cancer
26094080-10#161#165#gene3845 1837-1841 gene3845 denotes KRAS
26094080-10#142#156#diseaseC0001418 1818-1832 diseaseC0001418 denotes adenocarcinoma
0#5#gene283489170#196#diseaseC0007131 26094080-0#0#5#gene283489 26094080-0#170#196#diseaseC0007131 associated_with CHAMP,Non-Small-Cell Lung Cancer
0#5#gene54456170#196#diseaseC0007131 26094080-0#0#5#gene54456 26094080-0#170#196#diseaseC0007131 associated_with CHAMP,Non-Small-Cell Lung Cancer
227#231#gene3845170#196#diseaseC0007131 26094080-0#227#231#gene3845 26094080-0#170#196#diseaseC0007131 associated_with KRAS,Non-Small-Cell Lung Cancer
161#165#gene3845142#156#diseaseC0001418 26094080-10#161#165#gene3845 26094080-10#142#156#diseaseC0001418 associated_with KRAS,adenocarcinoma

DisGeNet-2017-sample

Id Subject Object Predicate Lexical cue
T2638 0-5 gene:283489 denotes CHAMP
T2639 170-196 disease:C0007131 denotes Non-Small-Cell Lung Cancer
R1 T2638 T2639 associated_with CHAMP,Non-Small-Cell Lung Cancer
R2 T2638 T2639 associated_with CHAMP,Non-Small-Cell Lung Cancer

UBERON-AE

Id Subject Object Predicate Lexical cue
PD-UBERON-AE-B_T1 185-189 http://purl.obolibrary.org/obo/UBERON_0002048 denotes Lung
PD-UBERON-AE-B_T2 522-526 http://purl.obolibrary.org/obo/UBERON_0002048 denotes lung
PD-UBERON-AE-B_T3 821-825 http://purl.obolibrary.org/obo/UBERON_0001460 denotes arms
PD-UBERON-AE-B_T4 1658-1661 http://purl.obolibrary.org/obo/UBERON_0001460 denotes arm
PD-UBERON-AE-B_T5 2005-2008 http://purl.obolibrary.org/obo/UBERON_0001460 denotes arm

performance-test

Id Subject Object Predicate Lexical cue
PD-UBERON-AE-B_T1 185-189 http://purl.obolibrary.org/obo/UBERON_0002048 denotes Lung
PD-UBERON-AE-B_T2 522-526 http://purl.obolibrary.org/obo/UBERON_0002048 denotes lung
PD-UBERON-AE-B_T3 821-825 http://purl.obolibrary.org/obo/UBERON_0001460 denotes arms
PD-UBERON-AE-B_T4 1658-1661 http://purl.obolibrary.org/obo/UBERON_0001460 denotes arm
PD-UBERON-AE-B_T5 2005-2008 http://purl.obolibrary.org/obo/UBERON_0001460 denotes arm